The fundamental inflection to profitability and raised guidance reduce cash runway risk. The $100M buyback signals management confidence. Watch for BMS' decision on PRX019 by year-end 2026, which could trigger a $55M milestone. Partner programs (prasinezumab, coramitug) continue de-risking.
PRTA drugs
PRTA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 8 $10.73entry
- T+1 · 6mo ago −9.88%α −10.11% · $9.67
- T+5 · 6mo ago −8.11%α −9.57% · $9.86
- T+20 · 5mo ago −18.08%α −18.10% · $8.79
- T+60 · 3mo ago −20.88%α −25.72% · $8.49
Price Chart
How similar events traded
Executive Summary
Prothena reported a transformative Q1 2026: net income of $32.7M (diluted EPS $0.60) vs. consensus loss of -$0.31, driven by a $50M milestone from Novo Nordisk and improved cost discipline. Revenue surged to $51.1M from $2.8M YoY. Guidance was raised significantly, with expected full-year net loss reduced to $25-30M (from $67-72M) and cash balance projected at $273M (up $18M from prior guidance). The company also initiated a $100M share repurchase program.
Key Financial Metrics
Key Facts
- Net income of $32.7M vs. net loss of $60.2M in Q1 2025; diluted EPS $0.60 vs. consensus -$0.31
- Total revenue of $51.1M, up from $2.8M, including a $50M milestone from Novo Nordisk for coramitug
- Updated guidance: FY2026 net cash used $18-23M (prior $50-55M), net loss $25-30M (prior $67-72M), ending cash ~$273M
- Initiated up to $100M share repurchase program; $7.3M repurchased in Q1
- Cash position $330.3M at quarter-end, zero debt
Financial Impact
EPS surprise of +$0.91 vs consensus, revenue grew 18x YoY, guidance improvement worth +$18M cash
Risk Factors
- Continued reliance on milestone payments for revenue; non-recurring $50M boosts current quarter
- Phase 3 trial outcomes for prasinezumab (2029) and coramitug (2029) remain binary
- Share repurchase may not be fully executed if cash needs change
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001559053-26-000016 |
| Document: prta-20260507.htm | 0001559053-26-000016 |
| Document: 0001559053-26-000016-index-headers.html | 0001559053-26-000016 |
| Document: 0001559053-26-000016-index.html | 0001559053-26-000016 |
| Document: 0001559053-26-000016.txt | 0001559053-26-000016 |
| 8-K Data (Synthetic) | 0001559053-26-000016 |
Track record
20 reports on PRTA
8 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +14.11% at T+60 after the Jun 12, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 13, 20263d ago 3 Neutral 1/10 Entry $8.16 to $7.97 Now $7.97 −2.33% ▼ −2.33% −0.42% vs SPY
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $8.16 to $7.97 Now $7.97 −2.33% ▼ −2.33% −0.42% vs SPY
- Nov 10, 20266d ago Insider Buy Bullish 5/10 Entry $8.56 to $8.73 Now $7.97 −6.89% ▲ +1.99% +0.67% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $7.97 to $8.78 Now $7.97 −0.00% ▲ +10.10% +7.73% vs SPY
- Oct 29, 202618d ago 8-K Bearish 6/10 Entry $8.47 to $8.29 Now $7.97 +5.90% ▲ +2.13% +1.65% vs SPY
- Oct 26, 202621d ago Insider Buy Bullish 5/10 Entry $8.81 to $9.10 Now $7.97 −9.53% ▲ +3.29% +2.95% vs SPY
- Oct 15, 20264w ago Insider Buy Bullish 5/10 Entry $8.35 to $8.48 Now $7.97 −4.55% ▲ +1.56% +1.13% vs SPY
- Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $8.54 to $8.36 Now $7.97 −6.67% ▼ −2.11% −2.85% vs SPY
- Sep 29, 20266w ago Insider Buy Bullish 5/10 Entry $8.38 to $8.54 Now $7.97 −4.89% ▲ +1.91% +1.73% vs SPY
- Sep 21, 20268w ago Insider Buy Bullish 6/10 Entry $8.99 to $8.68 Now $7.97 −11.35% ▼ −3.45% −2.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers